The development and commercialization of biosimilars require significant investment in capital, resources, and time. Biosimilar developers must ensure that they are equipped with the necessary…
The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and…
Since the approval of the first biosimilar in Europe more than a decade ago, the adoption of biosimilars has been increasing among all specialties. The FDA approved Sandoz’s Zarxio (filgrastim)…
asdfasdf
Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity…
In 2019, Amgen / Allergan's trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…
To determine the trade-offs across key biosimilar attributes that surveyed medical oncologists are willing to make when considering which biosimilar to prescribe, we included an adaptive choice-…
To determine the trade-offs across key biosimilar attributes that surveyed rheumatologists are willing to make when considering which biosimilar to prescribe, we included an adaptive choice-based…
The biosimilar / follow-on insulin sector of the diabetes therapy market is evolving. Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine…
The biosimilar / follow-on insulin sector of the diabetes therapy market is evolving. Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine…
In 2020, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $120 billion in the major pharmaceutical markets under study (United…
Clarivate’s biosimilars experts routinely analyze key market events via a presentation and commentary, available for playback at any time.
Payers play a significant role in determining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential…
Abstract here
Abstract here